



17 February 2020

ASX Announcement

Race appoints Australian Clinical Program Director

- **Dr Marinella Messina appointed Clinical Program Director to start on 16 March 2020**
 - **Dr Messina brings extensive experience in oncology clinical trials through all development phases**
 - **Will be establishing and running the Australian Bisantrone trials**
-

17 February 2020 – Race Oncology Limited (ASX: RAC) is pleased to welcome the highly experienced oncology clinical trials specialist, Dr Marinella Messina, as its Australian Clinical Program Director. Dr Messina will commence on 16 March 2020 and be responsible for progressing the Australian trials, part of the Company's new '5 path' strategy (refer ASX announcement: 14 November 2019).

Dr Messina has managed a wide range of clinical trials over the last ten years, across all development phases (I, II, III and IV). She has also worked with a number of pharmaceutical companies and research investigators during this time.

Dr Messina was previously employed at Datapharm, an Australian Clinical Research Organisation (CRO), where she progressed from a Clinical Research Associate to Senior Clinical Project Manager over a six-year period. During her time with Datapharm, she oversaw the start-up, recruitment and management of numerous clinical trials.

Dr Messina subsequently worked for ASX listed drug development biotech, Noxopharm Limited for nearly four years as both Clinical Operations Manager and Clinical Program Manager for Noxopharm's anti-cancer drug candidate Veylonda.

Dr Messina holds a Doctor of Philosophy from the Faculty of Medicine at the University of Sydney, and a Bachelor of Science (Honours) from the Department of Microbiology at the University of Sydney. She is also a Certified Medical Publication Professional and has published extensively in a broad range of peer-reviewed publications.

The Company is confident that Dr Messina's considerable experience in cancer clinical trials and medical writing will greatly assist Race in progressing the '5 path' strategy and associated Australian based clinical trials.

Management commentary:

Dr Daniel Tillett, RAC CSO, said: "I am very pleased to welcome Marinella into the Race Oncology team. I am confident that her background in clinical trial management and design, particularly in oncology, will prove invaluable as we advance Bisantrone in the clinic both in Australia and internationally."

- ENDS -

About Race Oncology (RAC: ASX)

Race Oncology (RAC) is a drug development biotech with a Phase II cancer drug called Bisantrene. RAC has compelling clinical data for Bisantrene in acute myeloid leukaemia (AML) as well as breast and ovarian cancer. RAC is pursuing an exciting '5-Path' clinical development strategy that involves parallel US and Australian clinical trials in AML and other cancers.

Release authorised by:

Peter Molloy, Managing Director
plmolloy@raceoncology.com

Media contact:

Heidi Cuthbert
+61 411 272 366
heidi.cuthbert@multiplier.com.au

Released through: Henry Jordan, Six Degrees Investor Relations: +61 (0) 431 271 538